Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women

被引:35
作者
Lewis, JG
McGill, H
Patton, VM
Elder, PA
机构
[1] Canterbury Hlth Labs, Steroid & Immunobiochem Lab, Christchurch, New Zealand
[2] Menopause & Womens Hormone Clin, Christchurch, New Zealand
关键词
progesterone; postmenopause; transdermal; saliva; hormone replacement therapy;
D O I
10.1016/S0378-5122(01)00250-X
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 [法学]; 0303 [社会学]; 100203 [老年医学];
摘要
Objectives: To determine the levels of progesterone in plasma, red cells and saliva as well as pregnanediol-3-glucuronide excretion in postmenopausal women using transdermal progesterone creams. Methods: A double-blind placebo controlled study was carried out using 24 postmenopausal women. Creams (placebo, 20 or 40 mg progesterone/g) were applied twice daily for 3 weeks followed by 1 week without before a further 3-week treatment. Morning samples were collected at 0, 1, 3, 4, 7 and 8 weeks for analysis. Results: There were small increases in plasma progesterone levels and pregnanediol-3-glucuronide excretion compared to the placebo group and red cell progesterone levels never exceeded plasma levels during progesterone cream use. Saliva progesterone levels were very high and variable in the progesterone cream groups compared to the placebo group and presented a paradox to the usual relationship observed between plasma and saliva progesterone in premenopausal women. Conclusion: The absorption of progesterone from transdermal creams is low and we caution against the use of saliva measurements to monitor progesterone absorption. The low systemic absorption of progesterone may not be due to peripheral conversion by 5alpha-reductase(s). We also conclude that the low level of progesterone associated with red cells suggests they are not important in the delivery of progesterone to target tissues. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 13 条
[1]
Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen [J].
Burry, KA ;
Patton, PE ;
Hermsmeyer, K .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (06) :1504-1510
[2]
A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women [J].
Carey, BJ ;
Carey, AH ;
Patel, S ;
Carter, G ;
Studd, JWW .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2000, 107 (06) :722-726
[3]
Systemic absorption of progesterone from Progest cream in postmenopausal women [J].
Cooper, A ;
Spencer, C ;
Whitehead, MI ;
Ross, D ;
Barnard, GJR ;
Collins, WP .
LANCET, 1998, 351 (9111) :1255-1256
[4]
Generation of monoclonal progesterone antibodies by electrofusion techniques [J].
Elder, PA ;
Gaynor, PT ;
Lewis, JG ;
Bodger, PS ;
Bason, LM .
BIOELECTROCHEMISTRY AND BIOENERGETICS, 1997, 43 (01) :35-40
[5]
THE PERMEABILITY OF THE HUMAN RED-CELL MEMBRANE TO STEROID SEX-HORMONES [J].
KOEFOED, P ;
BRAHM, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1994, 1195 (01) :55-62
[6]
Progesterone metabolism in human saliva in vitro [J].
Laine, MA ;
Ojanotko, AO .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 70 (1-3) :109-113
[7]
Lee JR, 1998, LANCET, V352, P905, DOI 10.1016/S0140-6736(05)60044-X
[8]
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss [J].
Leonetti, HB ;
Longo, S ;
Anasti, JN .
OBSTETRICS AND GYNECOLOGY, 1999, 94 (02) :225-228
[9]
REEXAMINING STEROID-HORMONE METABOLITES AS OVULATION MARKERS USING MONOCLONAL-ANTIBODIES [J].
LEWIS, JG ;
MANLEY, L ;
WHITLOW, JC ;
ELDER, PA .
STEROIDS, 1994, 59 (04) :288-291
[10]
THE ENZYME AND INHIBITORS OF 4-ENE-3-OXOSTEROID 5-ALPHA-OXIDOREDUCTASE [J].
LI, X ;
CHEN, CL ;
SINGH, SM ;
LABIRE, F .
STEROIDS, 1995, 60 (06) :430-441